Channel
@huhpharm
On this record: Topic · Growth · Engagement · What this channel posts · Posts · Citations · Telegram's recommendations · Cite this entry
24,260subscribers
+341 since we began measuring on 6 August 2026
Risers and fallers across the register · movement among entries of 10,000–31,623.
| Telegram ID | -1001381339396 |
|---|---|
| Type | Channel |
| Username | @huhpharm |
| Description | 제약/바이오 뉴스, 업데이트, 발간자료 공유 |
| Created | 12 July 2020 — measured — cross-checked against a third-party dataset (ext.tg_channel) |
| First recorded | 6 August 2026 |
| Last confirmed live | 31 October 2026 |
| Measurements held | 53 |
| Confirmed unchanged | 1 time, most recently 31 October 2026 |
| On Telegram | t.me/huhpharm |
Other / unclassifiable — a classification, not a measurement. An on-box language model (Qwen3.6-35B-A3B-FP8, prompt version 1) read this channel’s own recent posts on 10 September 2026 and assigned it the closest of 31 fixed categories, at 64% confidence. This is a model’s judgement about what the channel is likely to be about, not a fact this register measured the way a subscriber count or a view count is measured — it can be revised on a later pass, and it carries no weight anywhere else on this page. How this classification works, and the other topics.
| Measured (UTC) | Subscribers | Change |
|---|---|---|
| 31 Oct 2026, 14:36 | 24,260 | -5 |
| 30 Oct 2026, 13:48 | 24,265 | +9 |
| 29 Oct 2026, 13:36 | 24,256 | -3 |
| 28 Oct 2026, 16:08 | 24,259 | -7 |
| 27 Oct 2026, 17:04 | 24,266 | -3 |
| 26 Oct 2026, 15:19 | 24,269 | -2 |
| 25 Oct 2026, 13:27 | 24,271 | -6 |
| 23 Oct 2026, 11:38 | 24,277 | -9 |
| 22 Oct 2026, 08:35 | 24,286 | -2 |
| 21 Oct 2026, 04:00 | 24,288 | -6 |
| 20 Oct 2026, 01:18 | 24,294 | +2 |
| 19 Oct 2026, 04:19 | 24,292 | -5 |
| 18 Oct 2026, 02:39 | 24,297 | -4 |
| 17 Oct 2026, 05:47 | 24,301 | -1 |
| 16 Oct 2026, 05:18 | 24,302 | +9 |
| 15 Oct 2026, 03:40 | 24,293 | +7 |
| 14 Oct 2026, 02:56 | 24,286 | -9 |
| 11 Oct 2026, 17:16 | 24,295 | +6 |
| 7 Oct 2026, 08:54 | 24,289 | -19 |
| 2 Oct 2026, 12:01 | 24,308 | first reading |
312 posts held, back to 4 August 2026 — the reader has not yet reached the start of this channel’s public history, so older posts may sit further back, unread. Read across 111 pages of Telegram’s post history, 20 posts per page.
ERR is average views per post over the last 30 days divided by subscribers, the definition TGStat uses, so this figure is comparable with the one you will see elsewhere. It falls structurally as a channel grows: a high ERR on a small channel and a low one on a large channel describe reach mathematics, not quality. We publish the figure and the sample it came from and pass no verdict on it.
ER is defined industry-wide as (forwards + reactions + comments) ÷ views — note the denominator is views, not subscribers. Telegram’s public web preview carries views and reactions but not forward or comment counts, so the reaction rate above is the reactions term only and is therefore a floor: the true ER for this channel is higher by an amount we have not measured and will not estimate.
| Window | Rolling 30 days · latest post in window 30 October 2026 |
|---|---|
| Posts held | 312 (4 August 2026 – 30 October 2026) |
| Views total | 554,790 |
| Reactions total | — |
| Forwards / comments | not exposed by the public surface — not measured, not estimated |
| Readings taken | 31 Oct 2026, 15:51 UTC |
Views are a single reading per post, taken at the time above. A post published in the last day or two is still accumulating views, which pulls the 30-day average down slightly. That is a property of the standard definition rather than a fault in it, so we keep the definition rather than “correcting” the number into something nobody can reproduce.
Precision. Telegram publishes view counts on its public widget in short form — 8.12K, 3.7M — so any reading at or above 1,000 reaches us rounded to three significant figures, and only counts below 1,000 are exact. Averages and rates derived from them are shown to the same precision rather than to the unit: a figure like 3,701,250 would assert digits nobody measured.
Reaction counts are published per emoji and rounded the same way, so a total below 1,000 is exact and a larger one is a sum that may carry a rounded component from each emoji above 1,000. Because it is a sum, it does not look rounded — read a large reaction total as three significant figures per contributing emoji rather than as the figure it prints.
Lifetime counters from Telegram’s own channel header, read 31 October 2026 — not the date at the top of this page, which is when the subscriber count was last read. A count marked ≈ was rounded by Telegram before we ever saw it — t.me prints these counters in full below 1,000 and to three significant figures above, so ≈142,000 means somewhere between 141,500 and 142,499.
안녕하세요, 올릭스 커뮤니케이션실입니다. 주주 여러분께서 많이 기다리셨을 소식을 전해드립니다. 지난 9월 16일 승인 신청한 당사의 황반변성 치료제 ‘OLX301A’가 호주 인체연구윤리위원회(Bellberry HREC)로부터 임상 2a상 시험계획 승인을 획득하였습니다. OLX301A는 앞서 미국 임상 1상에서 안전성과 내약성을 확인한 바 있으며, 이번 임상 2a상에서는 총 64명의 지도 모양 위축(GA) 환자를 대상으로 약효를 본격적으로 검증할 예정입니다. 당사는 이번 승인을 발판으로 다국가 임상 개발을 차질 없이 추진하고, 잠재적 글로벌 파트너사들과의 기술이전 논의에도 더욱 박차를 가하겠습니다. 기다려 주신 주주 여러분께 감사드리며, 앞으로도 주요 개발 진행 상황을 신속하고 투명하게 안내드리겠습니다. 자세한 내용은 관련 공시를 참고…
Signed 혜민 허
2026.10.30 15:25:43 기업명: 올릭스(시가총액: 2조 1,411억) A226950 보고서명: 투자판단관련주요경영사항(임상시험계획승인신청등결정) * 임상명칭 : 양측성 지도 모양 위축(GA)을 동반한 노인성 황반변성(AMD) 환자를 대상으로 유리체강 내 주사로 투여하는 OLX10212의 유효성 및 안전성 평가를 위한 다기관, 무작위 배정, 모의 시술군 대조 제2a상 임상시험 (A Phase IIA, Multicenter, Randomized, Sham-Controlled Clinical Study to Evaluate the Efficacy and Safety of OLX10212 Administered by Intravitreal Injection in Participants with Bilateral Age-Related M…
Signed Jonghyun Kim
2026.10.30 13:40:17 기업명: 앱클론(시가총액: 3,713억) A174900 보고서명: 투자판단관련주요경영사항 (TIGIT 표적 항체신약 후보물질 도출 공동연구개발 및 기술이전의 건) 제목 : TIGIT 표적 항체신약 후보물질 도출 공동연구개발 및 기술이전의 건 * 주요내용 1) 계약상대방 : 유한양행 2) 계약의 내용 : 당사는 과거 체결(2016년)했던 TIGIT 표적 항체신약 후보물질 도출 공동연구개발계약과 관련하여, 상대방과의 합의를 통해 원계약을 이행 완결하고 관련 연구 결과물(후보물질 기술이전 등 권리 일체)을 상대방에 귀속 및 최종 정리하는 변경계약을 체결함. 3) 계약체결일 : 2026년 10월 30일 4) 정산금액 : 1,000,000,000원 공시링크: https://dart…
Signed 혜민 허
마운자로 27만원인데, 12만원?...비만약 '에페' 환승 https://www.mt.co.kr/thebio/2026/10/30/2026102919550231774
Signed 혜민 허
2026.10.30 07:42:50 기업명: 녹십자(시가총액: 1조 5,485억) A006280 보고서명: 투자판단관련주요경영사항 제목 : 파브리병 치료제(LA-GLA) 기술이전 계약 체결 * 주요내용 ※ 투자유의사항 동 계약은 기술이전 계약으로서, 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라 특정 사유 발생 시 계약이 해지될 수 있습니다. 1) 계약상대방 : BIOMARIN PHARMACEUTICAL INC.(미국) 2) 계약의 내용 - 파브리병(Fabry Disease) 치료를 위한 차세대 지속형 효소대체요법 LA-GLA(GC1134A) 기술이전 계약. - 계약기간 중 계약상대방에게 연구, 개발, 제조 및 상업화에 대한 독점적 라이선스를 부여함. 3) 계약체결일…
Signed 혜민 허
2026.10.30 07:42:24 기업명: 한미약품(시가총액: 5조 667억) A128940 보고서명: 투자판단관련주요경영사항 (파브리병 치료제(LAGLA) 기술이전 계약 체결) 제목 : 파브리병 치료제(LA-GLA) 기술이전 계약 체결 * 주요내용 ※ 투자유의사항 동 계약은 기술이전 계약으로서, 본 계약을 통한 수익 인식은 임상시험과 품목허가 등의 성공 여부에 따라 달라질 수 있습니다. 계약 조건에 따라, 특정 사유 발생시 계약이 해지될 수 있습니다. 1) 계약상대방: BIOMARIN PHARMACEUTICAL INC.(미국) 2) 계약의 내용: - 파브리병(Fabry Disease) 치료를 위한 차세대 지속형 효소대체요법 LA-GLA(HM15421) 기술이전 계약. - 계약기간 중 계약상대방에게 연구, …
Signed 혜민 허
26/10/30 (금) 키움 제약바이오 데일리 💊 [제약/바이오 Analyst 허혜민, RA 김종현] 키움 제약/바이오/의료기기 소식통: t.me/huhpharm <📈 주요 지수 등락> * 코스피 -1.24% vs 코스피 제약 -0.28% * 코스닥 -2.34% vs 코스닥 제약 -1.14% * S&P500 -0.3% vs XBI +0.18% * 나스닥 -1.38% vs NBI +0.86% <🇰🇷 국내 주요 뉴스 🔥> *괄호 안은 전일 수익률 ★ GC녹십자·한미약품, 美바이오마린에 '파브리병 신약물질' 기술이전…"최대 4억7500만달러 규모" (+1.15%) - 선급금 7000만달러·개발 및 상업화 마일스톤 최대 4억500만달러…로열티 별도 -> https://tinyurl.com/2yygswyc ▶ 삼성전자, 삼성바이오 유상증…
Signed Jonghyun Kim
한미약품이 MSD에 기술이전한 에피노페그듀타이드(Efinopegdutide, MK-6024)의 MASH 임상 2b상 결과가 미국간학회(AASLD)에서 발표될 예정으로 표기 간학회는 다음주(11/5~9) 입니다.
Signed 혜민 허
[키움 허혜민] 릴리, 3Q26 어닝 서프라이즈. 연간 매출 가이던스 대폭 상향 Eli Lilly, 3Q26 매출 $24.4bn, 조정 EPS $7.48 기록하며 시장 예상치 매출 $22.61bn, EPS $6.26 상회. 2026년 연간 매출 가이던스 $85~87bn → $91~92bn으로 상향. 조정 EPS 가이던스는 $35.50~36.50 → $35~36으로 하향. 3분기 M&A 관련 비용 $4.57/주 반영 영향 마운자로 매출 $10.72bn(+65% YoY)으로 컨센서스 $10.10bn 상회. 미국 매출 약 $5bn, 해외 매출 +93% 증가하며 글로벌 수요 확대 젭바운드 매출 $5.35bn(+49% YoY)으로 컨센서스 $5.09bn 상회. 판매량 증가에도 불구하고 미국 내 실현 판매가격 하락 지속 반면 지난 4월 미국 출…
Signed 혜민 허
[키움 허혜민] 한미약품·GC녹십자, 바이오마린에 최대 $475mn 기술이전 계약 체결 BioMarin, 한미약품·GC녹십자와 파브리병 치료제 HM15421/GC1134A에 대한 글로벌 독점 라이선스 계약 체결. 계약금 $70mn(약 1,000억원), 개발·상업화 마일스톤 최대 $405mn, 총 $475mn(약 6,800억원) 및 단계별 판매 로열티 별도 HM15421/GC1134A는 장기지속형 피하주사 효소대체요법(ERT) 치료제로, 현재 파브리병 환자 대상 임상 1/2상 진행 중. 기존 정맥주사 방식과 차별화된 최초의 피하주사 파브리병 ERT를 목표로 개발 전임상에서 신장 기능, 혈관 건강 및 말초신경계 관련 지표에서 차별화된 효능 확인. 2024년 미국 FDA 희귀의약품 지정 획득 BioMarin은 한국을 제외한 전 세계 개발·상…
Signed 혜민 허
Photo, posted without a caption
Signed 혜민 허
💡💡💡💡💡💡 Eli Lilly 2026년 3분기 실적 요약 📍실적 • 매출 $243.97억, YoY +39% • 매출총이익 $204.64억, YoY +40% • 매출총이익률 83.9%, YoY +100bps • 조정 매출총이익률 84.4%, YoY +80bps • 영업이익 $86.08억, YoY +17% • 순이익 $64.51억, YoY +16% • 조정 순이익 $66.79억, YoY +6% • GAAP EPS $7.22, YoY +16% • 조정 EPS $7.48, YoY +7% • 연구개발비 $42.47억, YoY +23% • 판매관리비 $31.25억, YoY +14% • 인수 관련 연구개발비 $41.81억, 전년 $6.56억 • 법인세 실효세율 23.3%, 전년 22.8% • 조정 법인세율 24.0%, 전년 17.7% • 주당 배당금 …
Signed 혜민 허
Showing the 12 most recent of 312 posts we hold for @huhpharm. View and reaction counts are the latest single reading for each post, not a live figure, and a recent post is still accumulating both. A view count marked ≈ was rounded by Telegram before we ever saw it — t.me prints views in full below 1,000 and to three significant figures above, so ≈1,200,000 means somewhere between 1,150,000 and 1,249,999. Unmarked counts are exact. Text is reproduced from the public post preview and truncated for length.
Republished by
Channels on the register that have forwarded this channel's posts into their own feed.
Republishes
Channels on the register whose posts this channel has forwarded.
Built only from forwarded posts we have actually read, on both sides. Coverage is early and deliberately incomplete: a missing link means we have not read the post that would prove it, never that the relationship does not exist. Counts are distinct forwarded posts observed, so they only ever go up as we read more.
Named by 9 registered channels — every channel on the register whose own posts have named this one, by its current username or any other username it currently holds, merged from two separately captured readings of the same fact so a namer caught by only one of them is not missed and a namer both caught is not counted twice. A username this channel has since dropped is not matched — that handle may belong to someone else now, and crediting today’s namer to yesterday’s owner would misattribute it.
Named by
Channels on the register whose posts name this channel's handle.
Names
Channels on the register whose handles appear in this channel's posts.
A mention is a weaker signal than a forward and is counted separately for that reason — naming a channel is not republishing it, and a handle in a post body is easy to place deliberately. The post counts beside each row below are distinct posts in which the handle appeared, from posts we have read on both sides — the “Named by N registered channels” figure above is a different count, of distinct NAMING CHANNELS rather than posts, and is not the sum of the rows under it.
Telegram’s own answer, not this register’s. When this register asks Telegram’s API what is similar to this channel, this is the list it returns, in the exact order Telegram returns it — never re-sorted by subscribers or by anything else this register measures. The relationship, and the order, are Telegram’s; we record them and date them, and make no claim of our own about which of these channels actually resemble this one.
Read from Telegram’s recommendation API, most recently 16 September 2026. Telegram holds a list like this for a small and growing share of the register — how this is measured, and why most channel pages show nothing here.
The reverse of the list above, and a different kind of signal. This does not require this channel to have ever been asked about directly — each row below is a channel we DID ask Telegram about, whose Telegram-generated list happened to include this one. A channel can appear here with an empty list above it, because being named by someone else’s query is independent of having been queried itself.
This channel appears in 10 seed channels' Telegram-generated recommendation lists in total. Each is Telegram’s list for THAT channel, not this one — see how this is measured.
A live page changes as we take new readings, so a citation should name the measurement it is based on, not just the URL. The line below cites the subscriber count as measured 31 October 2026 — this entry's latest reading, not the date you are reading this.
“허혜민의 제약/바이오 소식통” (@huhpharm), 24,260 subscribers as measured 31 October 2026. Telegram Register, tgregister.com/channel/huhpharm.
Full measurement history, CC BY 4.0. Every reading this register holds for this entry, not just the latest one, as a dated, downloadable record: CSV · JSON. Free to use with attribution to tgregister.com. Each file carries its own generation timestamp, which is the figure to cite for exactly when the data was retrieved.